Go to content
Crucell N.V.

Crucell N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 06 jan 2009 - 07:45
Statutaire naam Crucell N.V.
Titel Crucell Announces STAR® Research and Commercial License Agreement with Centocor, Inc.
Bericht Leiden, The Netherlands (January 6, 2009) – Dutch biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced a non-exclusive STAR® research and commercial license agreement with Pennsylvania-based Centocor, Inc. for the production of monoclonal antibodies. Financial details of the agreement were not disclosed. About STAR® Technology STAR® technology is a production technology that is particularly useful for the production of recombinant human antibodies and proteins. It has a potentially broad application and is effective for production of antibodies and proteins on mammalian cell lines such as Crucell's PER.C6® human cell technology and the widely used Chinese hamster ovary (CHO) cell line. STAR® technology contains genetic elements, called STAR® elements that enable stable and high-yield gene expression important to recombinant antibody and protein production in mammalian cells. The technology has the potential to increase production yields, thereby reducing production costs.